Petros Pharmaceuticals Inc

+0.01 (+0.34%)
Officer Changes, Mergers / Acquisitions

Neurotrope Shareholders To Own 49 Percent Of Petros Under Revised Merger Agreement With Metuchen

Published: 09/30/2020 14:11 GMT
(NTRP) - Neurotrope Shareholders to Own 49 Percent of Petros Under Revised Merger Agreement With Metuchen.
Neurotrope Inc - John Shulman, Founder and Managing Partner of Juggernaut Capital Partners, Will Become Executive Chairman of Board.
Neurotrope Inc - Company to Be Led by Fady Boctor As President and Chief Commercial Officer.
Neurotrope Inc - Neurotrope Shareholders, Currently Representing 34% of Shares Outstanding, Sign Agreement in Support of Merger.
Neurotrope Inc - Petros Will Explore Potential to Convert Stendra From Prescription-only Status to Non-prescription Status.